New scan seeks to uncover hidden brain inflammation in long COVID sufferers
NCT ID NCT06920628
First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 4 times
Summary
This study is testing whether a radioactive tracer called 11C-PS13 can detect brain inflammation in people who have long-term neurological symptoms after COVID-19. Researchers will compare PET scans from 60 adults (both healthy volunteers and those with long COVID) to see if the tracer highlights areas of inflammation. The goal is to better understand the biology behind brain fog, headaches, and other post-COVID brain issues.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 11C-PS13 (a radioactive tracer injected before a PET scan)
- What this could lead to
- If successful, this could help identify a biological marker for brain inflammation in long COVID, pointing toward new ways to diagnose or treat these symptoms.
- What could go wrong
- This is a very early Phase 1 study with only 60 participants. It is designed to measure inflammation, not to test a treatment, so it may not lead directly to any therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Feb 2029
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: Patients: To be eligible for this study, Neuro-PASC participants must meet all of the following criteria: * Aged 18 to 70 years of age. * Participants must be in good general health as evidenced by medical history and physical examination. * Each participant must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document. * Participants must have undergone a screening assessment under protocol #000089, Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health or #000711 Immunotherapy for Neurological Post-Acute Sequelae of SARSCoV-2 (INPASC) and determined to have neuro-PASC. * Participants must have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists. * Participants must agree to adhere to the lifestyle considerations. Healthy Volunteers: To be eligible to participate in this study, healthy volunteers must meet all of the following criteria: * Aged 18 to 70 years of age. * Able to provide informed consent. * Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment. * Does not have an active SARS-CoV-2 infection. The protocol will conform with NIH CC standards for documenting a participant does not have active SARS-CoV-2 infection. This may include screening interviews and/or testing. * Participants must be at least six weeks out since the onset of SARS-CoV-2 symptoms with no fever for at least one week. * Participants must report having at least one prior SARS-CoV-2 infection. * Be enrolled in 01M0254, The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers or 17M0181, Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies . * Have had their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists. * Agree to adhere to the lifestyle considerations. EXCLUSION CRITERIA: Participants with Neuro-PASC who meet any of the following criteria will be excluded from participation in this study: * Clinically significant abnormalities on EKG or laboratory testing based on individual clinical judgement. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Any lab value that is two times the upper limit or lower values, as per the investigator s judgment. Creatinine level \>1.3 mg/dL. * Participants should not have taken Non-Steroidal Anti-Inflammatory Drug (NSAID)s for two weeks prior to each PET scan. Corticosteroids (with the exception of topical steroids), or immunosuppressants (e.g. methotrexate) must not have been taken within one month prior to each PET scan. * Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs daily life functions. * Participants who have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy). * Are unable to travel to the NIH. * Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits as determined by the study team. * Have an inability to lie flat and/or lie still on the camera bed for at least two hours,including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the participant during the screening visit. * Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye. * Pregnancy or Breastfeeding Women. * HIV Infection. Healthy volunteers who meet any of the following criteria will be excluded from participation in this study: * Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). * Participants should not have taken Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for two weeks prior to the PET scan. Corticosteroids (with the exception of topical steroids), or immunosuppressants (e.g., methotrexate) must not have been taken within one month prior to the PET scan. * Participants with an active SARS-CoV-2 infection. * Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs daily life functions. * Are unable to travel to the NIH. * Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits. * Have an inability to lie flat and/or lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the participant during the screening visit. * Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye. * Pregnancy or Breastfeeding Women. * HIV Infection.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Long COVID are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can slow breathing retrain the nervous system to fight long COVID?
- Can a brain zapping headset restore focus after long COVID?
- Mindfulness may offer relief for long COVID sufferers
- Can wearables decode the mystery of fatigue?
- Beetroot juice: a natural boost against long COVID fatigue?
- A One-Two punch for long COVID? supplement and therapy put to the test